1. Home
  2. SON vs DFTX Comparison

SON vs DFTX Comparison

Compare SON & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonoco Products Company

SON

Sonoco Products Company

HOLD

Current Price

$53.23

Market Cap

5.5B

ML Signal

HOLD

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$45.61

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SON
DFTX
Founded
1899
N/A
Country
United States
United States
Employees
N/A
106
Industry
Containers/Packaging
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.9B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
SON
DFTX
Price
$53.23
$45.61
Analyst Decision
Buy
Strong Buy
Analyst Count
9
8
Target Price
$60.13
$38.50
AVG Volume (30 Days)
1.2M
4.5M
Earning Date
04-21-2026
05-04-2026
Dividend Yield
4.39%
N/A
EPS Growth
510.30
N/A
EPS
0.68
N/A
Revenue
$7,518,753,000.00
N/A
Revenue This Year
$0.10
N/A
Revenue Next Year
$1.82
N/A
P/E Ratio
$79.28
N/A
Revenue Growth
41.72
N/A
52 Week Low
$38.65
$14.62
52 Week High
$58.44
$49.20

Technical Indicators

Market Signals
Indicator
SON
DFTX
Relative Strength Index (RSI) 49.43 67.53
Support Level $50.96 $17.51
Resistance Level $58.08 $49.20
Average True Range (ATR) 1.60 3.32
MACD -0.27 -0.18
Stochastic Oscillator 28.03 65.18

Price Performance

Historical Comparison
SON
DFTX

About SON Sonoco Products Company

Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: